![Ji Li](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Dr. Ji Li is a President & Chief Executive Officer at Ufovax LLC, a Chief Executive Officer at Feixiang Chemicals (Zhangjiagang) Co., Ltd. and a President at Hipro Polymers, Inc. Dr. Li was previously employed as a Chief Executive Officer by Uvax Bio LLC, a Vice President by Solvay Specialty Chemicals Asia Pacific Pte Ltd., and a President by Suzhou HiPro Polymers Co., Ltd.
| Società | Posizione | Inizio |
|---|---|---|
Feixiang Chemicals (Zhangjiagang) Co., Ltd.
 Feixiang Chemicals (Zhangjiagang) Co., Ltd. Chemicals: SpecialtyProcess Industries Produces and distributes fatty specialty chemicals | Amministratore Delegato | 01/02/2011 |
Hipro Polymers, Inc. | Presidente | 01/02/2011 |
Ufovax LLC
 Ufovax LLC BiotechnologyHealth Technology Operates as biotechnology company which develops vaccines | Amministratore Delegato | 01/01/2018 |
| Società | Posizione | Fine |
|---|---|---|
Uvax Bio, LLC
 Uvax Bio, LLC Uvax Bio LLC is a biotech pharmaceutical company specializing in the development of next-generation vaccines using its proprietary 1c-sa®pnp platform, which utilizes stable, multi-layered protein nanoparticles to present rationally designed antigens that elicit broad and potent immune responses against infectious diseases. The company is based in Newark, DE. The company’s vaccine pipeline targets major health threats including HIV-1, MERS, pandemic influenza, RSV, HMPV, and Lassa fever. Uvax Bio holds exclusive worldwide rights to the 1c-sa®pnp platform and has an expanding portfolio of clinical and patented preclinical vaccine candidates. The company’s technology enables the production of virus-like protein particles that can display multiple stabilized antigens targeting a wide range of viral and bacterial diseases, produced using a single-step, universal, cell-based manufacturing process. The company was founded in 2018 by Ji Li, Jiang Zhu. Ji Li has been the CEO since 2018. | Amministratore Delegato | 04/02/2025 |
Solvay Specialty Chemicals Asia Pacific Pte Ltd.
 Solvay Specialty Chemicals Asia Pacific Pte Ltd. Chemicals: SpecialtyProcess Industries Manufactures basic and performance chemicals | Corporate Officer/Principal | - |
Suzhou HiPro Polymers Co., Ltd.
 Suzhou HiPro Polymers Co., Ltd. Oilfield Services/EquipmentIndustrial Services Manufactures and distributes bio-renewable polymades from natural resource cator oil | Presidente | - |
Attive
Inattive
Società nel listino
Aziende private
| Aziende private | 6 |
|---|---|
Feixiang Chemicals (Zhangjiagang) Co., Ltd.
Feixiang Chemicals (Zhangjiagang) Co., Ltd. Chemicals: SpecialtyProcess Industries Produces and distributes fatty specialty chemicals | Process Industries |
Suzhou HiPro Polymers Co., Ltd.
Suzhou HiPro Polymers Co., Ltd. Oilfield Services/EquipmentIndustrial Services Manufactures and distributes bio-renewable polymades from natural resource cator oil | Industrial Services |
Hipro Polymers, Inc. | |
Solvay Specialty Chemicals Asia Pacific Pte Ltd.
Solvay Specialty Chemicals Asia Pacific Pte Ltd. Chemicals: SpecialtyProcess Industries Manufactures basic and performance chemicals | Process Industries |
Ufovax LLC
Ufovax LLC BiotechnologyHealth Technology Operates as biotechnology company which develops vaccines | Health Technology |
Uvax Bio, LLC
Uvax Bio, LLC Uvax Bio LLC is a biotech pharmaceutical company specializing in the development of next-generation vaccines using its proprietary 1c-sa®pnp platform, which utilizes stable, multi-layered protein nanoparticles to present rationally designed antigens that elicit broad and potent immune responses against infectious diseases. The company is based in Newark, DE. The company’s vaccine pipeline targets major health threats including HIV-1, MERS, pandemic influenza, RSV, HMPV, and Lassa fever. Uvax Bio holds exclusive worldwide rights to the 1c-sa®pnp platform and has an expanding portfolio of clinical and patented preclinical vaccine candidates. The company’s technology enables the production of virus-like protein particles that can display multiple stabilized antigens targeting a wide range of viral and bacterial diseases, produced using a single-step, universal, cell-based manufacturing process. The company was founded in 2018 by Ji Li, Jiang Zhu. Ji Li has been the CEO since 2018. |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
